Market Place
Sourcing Support
All News #Library
Biotech
Pluri Bolsters Global IP With China Patent For Immune Cell
18 Feb 2026 //
GLOBENEWSWIRE
Pluri Completes First Phase of Resbiomed Biomaterials Program
22 Jan 2026 //
GLOBENEWSWIRE
Pluri Names Weinstein Chairman to Lead Strategic Shift
09 Dec 2025 //
GLOBENEWSWIRE
Pluri And Subsidiaries Named Bioagriculture Company Of The Year
13 Nov 2025 //
GLOBENEWSWIRE
Pluri Teams Up With Miss Universe Skincare For Exosome Skincare
11 Nov 2025 //
GLOBENEWSWIRE
NIH nixes financing for Pluri`s radiation exposure cell therapy
19 Apr 2025 //
FIERCE BIOTECH
Pluri`s IP Portfolio with 2 Patents for 3D Expansion of Immune Cells
10 Apr 2025 //
GLOBENEWSWIRE
Pluri Congratulates Mesoblast on FDA Approval for GvHD Cell Therapy
19 Dec 2024 //
GLOBENEWSWIRE
Pluri Evaluate PLX-R18 Mass Production for Acute Radiation Syndrome
25 Nov 2024 //
GLOBENEWSWIRE
Pluri Partners with Bar-Ilan University for Cancer Immunotherapy
28 Oct 2024 //
GLOBENEWSWIRE
NIH Funds $1.4M For Pluri`s PLX-R18 Acute Radiation Syndrome Contract Year 2
06 Jun 2024 //
GLOBENEWSWIRE
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method
18 Apr 2024 //
PRESS RELEASE
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method
08 Apr 2024 //
GLOBENEWSWIRE
Pluri Launches Cell Therapy Contract Development and Manufacturing Organization
08 Jan 2024 //
GLOBENEWSWIRE
Pluri Launches Global Cell Therapy CDMO
08 Jan 2024 //
CONTRACT PHARMA
Pluri and Bar-Ilan University to Develop PLX Cells for Cocaine Addiction
21 Dec 2023 //
GLOBENEWSWIRE
Pluri™s PLX-R18 Reduces Need for Transfusions in a Phase I Study
16 Aug 2023 //
GLOBENEWSWIRE
U.S. National Institutes of Health to Fund $4.2M Contract for Development of Pluris PLX-R18
11 Jul 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.